Gelteq receives FDA approval of its suitability petition for new animal drug

Gelteq (GELS) Limited announces that the U.S. Food and Drug Administration, FDA, has approved its suitability petition for a new animal drug under development. The new animal drug leverages Gelteq’s ingestible gel platform designed for nutrient and drug delivery. A suitability petition is a request by a drug sponsor to submit an abbreviated new animal drug application, ANADA, for a proposed innovative new animal drug that differs from a previously FDA approved generic animal drug.